Dan Zandberg, MD Introduction Currently, two immunotherapy medications, Nivolumab (Opdivo) and Pembrolizumab (Keytruda) are approved in the USA for recurrent and or metastatic squamous cell carcinoma of head and neck (HNSCC) after a patient received and failed “platinum” based chemotherapy. Both Nivolumab...
Robert L. Ferris, MD, PhD Clinical trials are a key research tool for advancing medical knowledge and patient care. Clinical research is done only if doctors do not know whether a new approach works well in people and is safe and...
Liza Murray, APRN & Allen M. Chen, MD What is cancer survivorship? Survivorship focuses on the health and life of a person with cancer from initiation of treatment until the end of life. It covers the physical, psychosocial and economic issues of...
Liza Murray, APRN & Allen M. Chen, MD We’re back! We’d like to expand on our survivorship topics from September’s newsletter and highlight more survivorship challenges for head and neck cancer patients. We appreciate the feedback and insight from our part...
